TE1 주식 개요 Bio-Techne Corporation은 자회사와 함께 전 세계 연구, 진단 및 바이오 프로세싱 시장을 위한 생명과학 시약, 기기 및 서비스를 개발, 제조 및 판매하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Bio-Techne Corporation 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Bio-Techne 과거 주가 현재 주가 US$69.00 52주 최고치 US$78.50 52주 최저치 US$57.50 베타 1.27 1개월 변경 -2.82% 3개월 변경 사항 3.76% 1년 변경 사항 4.55% 3년 변화 -26.98% 5년 변화 43.01% IPO 이후 변화 502.88%
최근 뉴스 및 업데이트
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo Nov 14
New minor risk - Earnings quality Nov 08
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer (SITC) 39Th Annual Meeting Nov 06
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data Nov 05
First quarter dividend of US$0.08 announced Nov 04
First quarter 2025 earnings released: EPS: US$0.21 (vs US$0.32 in 1Q 2024) Nov 01 더 많은 업데이트 보기
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo Nov 14
New minor risk - Earnings quality Nov 08
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer (SITC) 39Th Annual Meeting Nov 06
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data Nov 05
First quarter dividend of US$0.08 announced Nov 04
First quarter 2025 earnings released: EPS: US$0.21 (vs US$0.32 in 1Q 2024) Nov 01
Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2024, Payable on November 22, 2024 Oct 30
ScaleReady and Bio-Techne Corporation Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies Sep 16
Bio-Techne Corporation, Annual General Meeting, Oct 24, 2024 Sep 13
Fourth quarter dividend of US$0.08 announced Aug 12
Full year 2024 earnings released: EPS: US$1.07 (vs US$1.81 in FY 2023) Aug 08
Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2024, Payable on August 30, 2024 Aug 07
Bio-Techne Corporation Announces the Launch of the Leo™ System Jul 31
Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex™? System at the Annual ASMS Conference May 30
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration May 23
Investor sentiment improves as stock rises 21% May 08
Third quarter dividend of US$0.08 announced May 05
Third quarter 2024 earnings released: EPS: US$0.31 (vs US$0.45 in 3Q 2023) May 02
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024 May 01
Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors Apr 30
Now 20% overvalued Apr 30
Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay Apr 27
Independent Director recently sold €733k worth of stock Mar 12
Second quarter dividend of US$0.08 announced Feb 05
Second quarter 2024 earnings released: EPS: US$0.17 (vs US$0.32 in 2Q 2023) Feb 02
Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended December 31, 2023, Payable February 26, 2024 Feb 02
Bio-Techne Corporation Sets New Standard with the Development of A Next-Generation, Protease-Free RNAscope Spatial Multiomics Workflow Jan 29
Now 22% overvalued after recent price rise Jan 24
Bio-Techne Corporation to Report Q2, 2024 Results on Feb 01, 2024 Jan 17 Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024
Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended September 30, 2023, Will Be Payable November 24, 2023 Nov 01
First quarter 2024 earnings released: EPS: US$0.32 (vs US$0.57 in 1Q 2023) Nov 01
Bio-Techne Corporation to Present New Data Using Lunaphore's Comet Technology at the Society for Immunotherapy of Cancer's 38th Annual Meeting Oct 27 Bio-Techne Corporation Announces Executive Changes
Bio-Techne Corporation Launches the New Maurice Chromeleon Driver Kit, Which Enables Control of its Maurice™ Instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System Sep 27
Bio-Techne Corporation, Annual General Meeting, Oct 26, 2023 Sep 14
Full year 2023 earnings released: EPS: US$1.82 (vs US$1.73 in FY 2022) Aug 09
Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others. Jul 11
Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA. Jun 23
Bio-Techne Corporation Announces Launch of Kappa and Lambda Rnascope Ish Probes as Analyte Specific Reagents (Asrs) for the Detection of Immunoglobulin Kappa and Lambda Light Chains mRNA May 11
Bio-Techne Declares Quarterly Dividend, Payable May 26, 2023 May 04
Third quarter 2023 earnings released: EPS: US$0.45 (vs US$0.39 in 3Q 2022) May 03
Second quarter 2023 earnings released: EPS: US$0.32 (vs US$0.51 in 2Q 2022) Feb 05
Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2022, Payable on February 27, 2023 Feb 03
Bio-Techne Corporation Announces Executive Changes, Effective March 3, 2023 Feb 01
Bio-Techne Launches the Mauriceflex™ System, Adding Cief Fractionation Capability to the Gold Standard Maurice Assays Jan 27
Bio-Techne Corporation Launches RNAscope Plus Assay to Advance Gene Therapy Development Jan 11
Bio-Techne Releases MitoBrilliant Fluorescent Dyes, Providing A Next-Generation Tool for Imaging Mitochondria in Live and Fixed Cells Dec 06
Insufficient new directors Nov 16
First quarter 2023 earnings released: EPS: US$2.28 (vs US$1.78 in 1Q 2022) Nov 02
Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2022, Payable on November 28, 2022 Nov 02
Bio-Techne Corporation Announces the Introduction of 3 Novel TSA Vivid Fluorophores for Highly Sensitive Fluorescent Detection of RNAs and Proteins in Cells and Tissues Oct 13
Bio-Techne Corporation and PROGEN Introduce New Simple Plex AAV Viral Titer Assays Oct 12
Bio-Techne Corporation Commercializes Automated Multi-Omic Rnascope Assays for Spatial Visualization of RNA and Protein Biomarkers in FFPE Tissues Oct 07
Bio-Techne Corporation, Annual General Meeting, Oct 27, 2022 Sep 02
Bio-Techne Corporation Announces Release of Quantist Luminex Data Analysis Software Aug 19
Full year 2022 earnings released: EPS: US$6.94 (vs US$3.62 in FY 2021) Aug 05 Bio-Techne Corporation Announces Dividend for the Quarter Ended June 30, 2022, Payable on August 29, 2022
Insufficient new directors Aug 01
Bio-Techne Launches New Turbo CE-SDS ™ Cartridge, Accelerating Protein Purity Analysis Throughput by 400% Jul 13
Bio-Techne Announces Launch of the CE-IVD RNAscope ISH Probe High Risk HPV Assay for Head and Neck Cancer Jul 07
Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Namocell, Inc. Jul 06
Insufficient new directors Jul 02 Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Growth-Defensive Index
Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Namocell, Inc. Jun 23
Bio-Techne Corporation Announces the Publication of A Global Study in the Journal of Electrophoresis May 26
Independent Chairman of the Board recently bought €100k worth of stock May 12
Third quarter 2022 earnings released: EPS: US$1.55 (vs US$1.18 in 3Q 2021) May 05
Bio-Techne Corporation Declares Quarterly Dividend for the Quarter Ended March 31, 2022, Payable on May 27, 2022 May 05
Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduces New Simple Plex Hek 293 Hcp 3G Immunoassay Apr 13
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 04 Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2021, Payable on February 25, 2022
Now 20% undervalued after recent price drop Jan 28
Bio-Techne Corporation Announces Commercial Release of High Sensitivity Fluorescent Detection Stellar NIR / IR™ Modules for Jess Automated Western Blotting System Jan 19
First quarter 2022 earnings released: EPS US$1.78 (vs US$0.87 in 1Q 2021) Nov 03
Bio-Techne Launches ExCellerate iPSC Expansion Medium Sep 15
President of Protein Sciences Segment recently sold €656k worth of stock Sep 03
Full year 2021 earnings released: EPS US$3.62 (vs US$6.00 in FY 2020) Aug 06 Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000E Value Index
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Value-Defensive Index Jun 27
President of Diagnostics & Genomics recently sold €288k worth of stock Jun 12
President of Diagnostics & Genomics recently sold €293k worth of stock May 28
Bio-Techne Corporation Announces Results of A Multisite Evaluation Study of the AmplideX May 11
Third quarter 2021 earnings released: EPS US$1.18 (vs US$0.95 in 3Q 2020) May 08
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2021, Payable on May 28, 2021 May 07
Bio-Techne Announces Commercial Release of Novel DNAscope™ in situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations Apr 29
Bio-Techne Corporation (NasdaqGS:TECH) has reached an agreement to acquire Asuragen, Inc for $320 million. Mar 05
Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana Mar 03
Bio-Techne and Luminary Therapeutics Sign License Agreement for Use of Bio-Techne's Tcbuster™ for the Development of Luminary's Car-T Cell Therapies Feb 24
New 90-day high: €342 Feb 18
Bio-Techne Corporation Announces That the U.S. Food and Drug Administration Added Covid-Seroklir to the Emergency Use Authorization Feb 11 주주 수익률 TE1 DE Life Sciences DE 마켓 7D -0.7% 0.2% 0.7% 1Y 4.5% -2.4% 8.4%
전체 주주 수익률 보기
수익률 대 산업: TE1 지난 1년 동안 -2.4 %를 반환한 German Life Sciences 산업을 초과했습니다.
수익률 대 시장: TE1 지난 1년 동안 8.4 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is TE1's price volatile compared to industry and market? TE1 volatility TE1 Average Weekly Movement 5.3% Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: TE1 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: TE1 의 주간 변동성 ( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 Bio-Techne Corporation은 자회사와 함께 전 세계 연구, 진단 및 바이오 프로세싱 시장을 위한 생명과학 시약, 기기 및 서비스를 개발, 제조 및 판매하고 있습니다. 이 회사는 단백질 과학과 진단 및 유전체학의 두 부문으로 운영되고 있습니다. 단백질 과학 부문은 사이토카인 및 성장 인자, 항체, 저분자, 조직 배양 혈청, 세포 선택 기술 등 생명 과학 연구, 진단, 세포 및 유전자 치료의 다양한 측면에서 사용되는 생물학적 시약을 개발 및 제조합니다.
자세히 보기 Bio-Techne Corporation 기본 사항 요약 Bio-Techne 의 수익과 매출은 시가총액과 어떻게 비교하나요? TE1 기본 통계 시가총액 €11.15b 수익(TTM ) €146.82m 수익(TTM ) €1.14b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) TE1 손익 계산서(TTM ) 수익 US$1.17b 수익 비용 US$398.40m 총 이익 US$773.19m 기타 비용 US$622.50m 수익 US$150.68m
주당 순이익(EPS) 0.95 총 마진 65.99% 순이익 마진 12.86% 부채/자본 비율 14.0%
TE1 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/02 11:16 장 마감 주가 2025/01/02 00:00 수익 2024/09/30 연간 수익 2024/06/30
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Bio-Techne Corporation 27 애널리스트 중 14 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 David Toung Argus Research Company James Francis Mainwaring Atlantic Equities LLP Catherine Ramsey Schulte Baird
24 더 많은 분석가 보기 
